Literature DB >> 28045522

Model-Based Discovery of Synthetic Agonists for the Zn2+-Sensing G-Protein-Coupled Receptor 39 (GPR39) Reveals Novel Biological Functions.

Thomas M Frimurer1, Franziska Mende, Anne-Sofie Graae, Maja S Engelstoft, Kristoffer L Egerod, Rie Nygaard, Lars-Ole Gerlach, Jakob Bondo Hansen, Thue W Schwartz, Birgitte Holst.   

Abstract

The G-protein-coupled receptor 39 (GPR39) is a G-protein-coupled receptor activated by Zn2+. We used a homology model-based approach to identify small-molecule pharmacological tool compounds for the receptor. The method focused on a putative binding site in GPR39 for synthetic ligands and knowledge of ligand binding to other receptors with similar binding pockets to select iterative series of minilibraries. These libraries were cherry-picked from all commercially available synthetic compounds. A total of only 520 compounds were tested in vitro, making this method broadly applicable for tool compound development. The compounds of the initial library were inactive when tested alone, but lead compounds were identified using Zn2+ as an allosteric enhancer. Highly selective, highly potent Zn2+-independent GPR39 agonists were found in subsequent minilibraries. These agonists identified GPR39 as a novel regulator of gastric somatostatin secretion.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28045522     DOI: 10.1021/acs.jmedchem.6b00648

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Modulation of Gpr39, a G-protein coupled receptor associated with alcohol use in non-human primates, curbs ethanol intake in mice.

Authors:  Verginia C Cuzon Carlson; Matthew M Ford; Timothy L Carlson; Alejandro Lomniczi; Kathleen A Grant; Betsy Ferguson; Rita P Cervera-Juanes
Journal:  Neuropsychopharmacology       Date:  2019-01-05       Impact factor: 7.853

2.  The expression and clinical significance of GPR39 in colon cancer.

Authors:  Xiaoqian Wu; Yingfei Dou; Hankun Xu; Zhichao Jiang
Journal:  Ir J Med Sci       Date:  2021-09-29       Impact factor: 2.089

Review 3.  Leveraging the Gut to Treat Metabolic Disease.

Authors:  Ruth E Gimeno; Daniel A Briere; Randy J Seeley
Journal:  Cell Metab       Date:  2020-03-17       Impact factor: 27.287

4.  Systematic Meta-Analysis Identifies Co-Expressed Kinases and GPCRs in Ovarian Cancer Tissues Revealing a Potential for Targeted Kinase Inhibitor Delivery.

Authors:  Hugo Albrecht; Eric Kübler
Journal:  Pharmaceutics       Date:  2019-09-02       Impact factor: 6.321

Review 5.  The Zinc-Sensing Receptor GPR39 in Physiology and as a Pharmacological Target.

Authors:  Anna Laitakari; Lingzhi Liu; Thomas M Frimurer; Birgitte Holst
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

Review 6.  The Zinc Sensing Receptor, ZnR/GPR39, in Health and Disease.

Authors:  Michal Hershfinkel
Journal:  Int J Mol Sci       Date:  2018-02-01       Impact factor: 5.923

7.  Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91.

Authors:  Mette Trauelsen; Elisabeth Rexen Ulven; Siv A Hjorth; Matjaz Brvar; Claudia Monaco; Thomas M Frimurer; Thue W Schwartz
Journal:  Mol Metab       Date:  2017-09-30       Impact factor: 7.422

8.  Orchestration of Intracellular Circuits by G Protein-Coupled Receptor 39 for Hepatitis B Virus Proliferation.

Authors:  Kaku Goto; Hironori Nishitsuji; Masaya Sugiyama; Nao Nishida; Masashi Mizokami; Kunitada Shimotohno
Journal:  Int J Mol Sci       Date:  2020-08-07       Impact factor: 5.923

Review 9.  Role of GPR39 in Neurovascular Homeostasis and Disease.

Authors:  Yifan Xu; Anthony P Barnes; Nabil J Alkayed
Journal:  Int J Mol Sci       Date:  2021-07-30       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.